Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

Notice of Proposed Rulemaking (NPRM): Proposed Rescheduling of Marijuana

Posted 5/18/2024

Proposed Rescheduling of Marijuana

Below are links available through the DEA website regarding various documents associated with the proposed rescheduling action. Included is the HHS recommendation dated August 29, 2023, prior DEA denials for rescheduling, and a question-and-answer document from the Department of Justice, Office of Legal Counsel.

There will be a 60-day comment period that includes the possibility of a request for a hearing, required within 30 days of publication.

Notice of Proposed Rulemaking (NPRM): Proposed Rescheduling of Marijuana

Notice of Proposed Rulemaking: Proposed Rescheduling of Marijuana
Basis for the Recommendation to Reschedule Marijuana into Schedule III of the Controlled Substances Act
Denial of Petition to Initiate Proceeding to Reschedule Marijuana Docket No. DEA-427
Denial of Petition to Initiate Proceeding to Reschedule Marijuana Docket No. DEA-426
Questions to OLC Related to the Potential Rescheduling of Marijuana

Back to all news

Sponsor Spotlight

COMPASS Pathways


COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more https://www.compasspathways.com

All Sponsors